P&MA Assessment to Support BD&L Decision-Making

Home / Intelligence / Case Studies / P&MA Assessment to Support BD&L Decision-Making

Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making.

Geographic Scope: US Flag

Client Situation

The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making.

Trinity’s Solution

Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.


  • Landscape assessment and analogue assessment across key markets
  • Payer & KOL moderator guides and research stimuli
  • Interim research findings summary
  • Detailed final research findings summary
  • Strategic business development and licensing (BD&L) recommendations and differentiation opportunities

Project Outcomes & Impact

The strategic guidance that Trinity delivered informed the client’s decision not to move forward with the acquisition of the LHON gene therapy asset.

Related Intelligence


Gene Therapy Uptake: The Elephant in the Room

Available On Demand

How can companies maximize their potential when launching a gene therapy product? Gene therapy commercialization is in its infancy. Limited commercial precedent creates significant difficulty in modeling gene therapy revenue and uptake. The single administration nature of the products also presents a unique challenge for companies as the eligible patient population decreases over time. In […]

 Watch Now

White Papers

Gene Therapy Uptake: The Elephant in the Room

Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size. In this white […]

 Read More


Valuing an Early-Stage Asset in Pharma and Biotech: Innovative Approaches for Novel Therapies

Available On Demand

Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets. Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies […]

 Watch Now